{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:05:03Z","timestamp":1770271503229,"version":"3.49.0"},"reference-count":17,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Epistaxis is the most prevalent clinical symptom in Hereditary Haemorrhagic Telangiectasia (HHT), causing anaemia and decreasing the quality of life (QOL). Since 2013, in Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, more than 150 HHT patients have been treated by nose sclerotherapy on demand. This study shows the results of 105 patients treated with sclerotherapy between 2017 and 2019. HHT-ESS (epistaxis severity score) was used to measure the severity and frequency of epistaxis. QOL was determined before and after treatment by EuroQol-5D (EQ-5D) and the visual analogue scale (VAS) on the health condition. According to HHT-ESS before treatment, 22 patients presented mild, 35 moderate, and 47 severe epistaxes. Sclerotherapy significantly decreased the frequency and severity of epistaxis, with a significant drop of HHT-ESS in 4.6 points, from 6.23 \u00b1 2.3 to 1.64 \u00b1 1.6. Furthermore, the QOL significantly improved, the EQ-5D scale raised from 0.7 \u00b1 0.26 pre- to 0.92 \u00b1 0.16 post-treatment (p &lt; 0.05). Additionally, VAS mean value showed a significant increase from 4.38 \u00b1 2.4 to 8.35 \u00b1 1.2. The QOL improvement was correlated with the ESS decrease. In conclusion, this study shows that on-demand sclerotherapy at the office significantly reduces HHT epistaxis as well as improved the patients\u2019 QOL.<\/jats:p>","DOI":"10.3390\/jcm10173845","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:01:37Z","timestamp":1630321297000},"page":"3845","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-8886","authenticated-orcid":false,"given":"Sol","family":"Marcos","sequence":"first","affiliation":[{"name":"Otorrhinolaringology Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, 28922 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-2245","authenticated-orcid":false,"given":"Luisa Mar\u00eda","family":"Botella","sequence":"additional","affiliation":[{"name":"CIBER Rare Diseases Unit 707, Centro de Investigaciones Biol\u00f3gicas Margarita Salas, CSIC, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Albi\u00f1ana","sequence":"additional","affiliation":[{"name":"CIBER Rare Diseases Unit 707, Centro de Investigaciones Biol\u00f3gicas Margarita Salas, CSIC, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustina","family":"Arbia","sequence":"additional","affiliation":[{"name":"Otorrhinolaringology Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, 28922 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Mar\u00eda","family":"de Rosales","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, 28922 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","first-page":"191","article-title":"Optimal management of hereditary hemorrhagic telangiectasia","volume":"5","author":"Garg","year":"2014","journal-title":"J. Blood Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for Hereditary Hemorrhagic Telangiectasia (Rendu- Osler-Weber Syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1523-1747.ep12555569","article-title":"Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia","volume":"95","author":"Braverman","year":"1990","journal-title":"J. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","article-title":"The Natural History of Epistaxis in Hereditary Hemorrhagic Telangiectasia","volume":"101","author":"Aassar","year":"1991","journal-title":"Laryngoscope"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/alr.21484","article-title":"Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia","volume":"5","author":"Boyer","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Albi\u00f1ana, V., Cuesta, A.M., Rojas, P.I., Gallardo-Vara, E., Recio-Poveda, L., Bernab\u00e9u, C., and Botella, L.M. (2020). Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061766"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4193\/Rhino11.142","article-title":"Local sclerotherapy with polydocanol (Aethoxysklerol\u00ae) for the treatment of epistaxis in Rendu-Osler-Weber or hereditary hemorrhagic telangiectasia (HHT): 15 years of experience","volume":"50","author":"Morais","year":"2012","journal-title":"Rhinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/lary.27930","article-title":"Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis","volume":"129","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_10","first-page":"1044","article-title":"Natural History of Epistaxis in a Spanish Population with Hereditary Haemorrhagic Telangiectasia (HHT)","volume":"3","author":"Zarrabeitia","year":"2016","journal-title":"Ann. Vasc. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0212-6567(01)70406-4","article-title":"EuroQol-5D: A simple alternative for measuring health-related quality of life in primary care","volume":"28","author":"Herdman","year":"2001","journal-title":"Aten. Primaria"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: A randomized clinical trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12955-017-0586-z","article-title":"Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)","volume":"15","author":"Zarrabeitia","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/lary.27889","article-title":"Injection of Bevacizumab and Cyanoacrylate for Hereditary Hemorrhagic Telangiectasia","volume":"129","author":"Khoueir","year":"2019","journal-title":"Laryngoscope"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3845\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:34Z","timestamp":1760165614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":17,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10173845"],"URL":"https:\/\/doi.org\/10.3390\/jcm10173845","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}